Clinically significant immune-mediated hematologic adverse reactions (including hemolytic anemia, aplastic anemia, immune thrombocytopenic purpura) transpired at an incidence of less than 1% in patients who been given this drug or ended up reported with the usage of other PD-one/PD-L1 blocking antib